CorMedix (CRMD) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of CorMedix (NYSEAMERICAN:CRMD) from a hold rating to a buy rating in a report published on Monday morning. Zacks Investment Research currently has $0.25 target price on the biotechnology company’s stock.

According to Zacks, “CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Company’s therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy. Its product pipeline includes: CRMD001, a unique formulation Deferiprone which is in development to prevent Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; CRMD002, a diagnostic test for urinary labile iron; CRMD003 (Neutrolin┬«, an antimicrobial/anticoagulant solution) is in development to prevent Catheter Related Bloodstream Infection; CRMD004, a pressure sensitive gel which has many uses, including extending the benefits of Neutrolin┬«. CorMedix Inc. is based in Summit, New Jersey. “

How to Become a New Pot Stock Millionaire

Separately, HC Wainwright set a $4.00 target price on CorMedix and gave the company a buy rating in a report on Monday.

CorMedix stock opened at $0.25 on Monday. CorMedix has a one year low of $0.17 and a one year high of $1.54.

Several hedge funds have recently made changes to their positions in the company. Virtu Financial LLC increased its position in shares of CorMedix by 126.4% in the fourth quarter. Virtu Financial LLC now owns 226,748 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 126,610 shares in the last quarter. Spinnaker Capital LLC purchased a new position in shares of CorMedix in the fourth quarter valued at $202,000. Finally, Vanguard Group Inc. increased its position in shares of CorMedix by 3.0% in the second quarter. Vanguard Group Inc. now owns 1,208,894 shares of the biotechnology company’s stock valued at $518,000 after buying an additional 35,148 shares in the last quarter.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3334184/cormedix-crmd-stock-rating-upgraded-by-zacks-investment-research.html.

CorMedix Company Profile

CorMedix Inc is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

Get a free copy of the Zacks research report on CorMedix (CRMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Green Bancorp  Receives Consensus Recommendation of “Hold” from Brokerages
Green Bancorp Receives Consensus Recommendation of “Hold” from Brokerages
Baker Hughes, a GE  Issues  Earnings Results
Baker Hughes, a GE Issues Earnings Results
Rayonier  Receives Consensus Rating of “Hold” from Brokerages
Rayonier Receives Consensus Rating of “Hold” from Brokerages
DEW  Price Tops $0.68
DEW Price Tops $0.68
indaHash 1-Day Volume Tops $71,069.00
indaHash 1-Day Volume Tops $71,069.00
Industrial Logistics Properties Trust  Announces Quarterly Dividend of $0.27
Industrial Logistics Properties Trust Announces Quarterly Dividend of $0.27


© 2006-2018 Ticker Report. Google+.